Congestive heart failure (HF) is a progressive affliction defined as the inability of the heart to sufficiently maintain blood flow. Ventricular arrhythmias (VAs) are common in patients with HF, and conversely, advanced HF promotes the risk of VAs. Management of VA in HF requires a systematic, multimodality approach that comprises optimization of medical therapy and use of implantable cardioverter-defibrillator and/or device combined with cardiac resynchronization therapy. Catheter ablation is one of the most important strategies with the potential to abolish or decrease the number of recurrences of VA in this population. It can be a curative strategy in arrhythmia-induced cardiomyopathy and may even save lives in cases of an electrical storm. Additionally, modulation of the autonomic nervous system and stereotactic radiotherapy have been introduced as novel methods to control refractory VAs. In patients with end-stage HF and refractory VAs, an institution of the mechanical circulatory support device and cardiac transplant may be considered. This review aims to provide an overview of current evidence regarding management strategies of VAs in HF with an emphasis on interventional treatment.

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. PubMed

Myerburg R.J., Junttila M.J. Sudden cardiac death caused by coronary heart disease. Circulation. 2012;125:1043–1052. PubMed

Stecker E.C., Reinier K., Marijon E., et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol. 2014;7:212–217. PubMed PMC

MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) Lancet. 1999;353:2001–2007. PubMed

Santangeli P., Rame J.E., Birati E.Y., Marchlinski F.E. Management of ventricular arrhythmias in patients with advanced heart failure. J Am Coll Cardiol. 2017;69:1842–1860. PubMed

Tomaselli G.F., Rose J. Molecular aspects of arrhythmias associated with cardiomyopathies. Curr Opin Cardiol. 2000;15:202–208. PubMed

Saxon L.A., Bristow M.R., Boehmer J., et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2006;114:2766–2772. PubMed

Powell B.D., Saxon L.A., Boehmer J.P., et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol. 2013;62:1674–1679. PubMed

Healey J.S., Hohnloser S.H., Glikson M., et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE) Lancet. 2015;385:785–791. PubMed

Carson P., Anand I., O’Connor C., et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2329–2334. PubMed

van der Heijden A.C., Höke U., Thijssen J., et al. Super-responders to cardiac resynchronization therapy remain at risk for ventricular arrhythmias and benefit from defibrillator treatment. Eur J Heart Fail. 2014;16:1104–1111. PubMed

Sapp J.L., Parkash R., Wells G.A., et al. Cardiac resynchronization therapy reduces ventricular arrhythmias in primary but not secondary prophylactic implantable cardioverter defibrillator patients: insight from the Resynchronization in Ambulatory Heart Failure Trial. Circ Arrhythm Electrophysiol. 2017;10 PubMed

Sacher F., Reichlin T., Zado E.S., et al. Characteristics of ventricular tachycardia ablation in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2015;8:592–597. PubMed

Efimova E., Fischer J., Bertagnolli L., et al. Predictors of ventricular arrhythmia after left ventricular assist device implantation: a large single-center observational study. Heart Rhythm. 2017;14:1812–1819. PubMed

Al-Gobari M., El Khatib C., Pillon F., Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52. PubMed PMC

Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321. PubMed

McMurray J.J.V., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. PubMed

Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–412. PubMed

Viskin S., Chorin E., Viskin D., et al. Quinidine-responsive polymorphic ventricular tachycardia in patients with coronary heart disease. Circulation. 2019;139:2304–2314. PubMed

Li D.L., Cox Z.L., Richardson T.D., et al. Quinidine in the management of recurrent ventricular arrhythmias: a reappraisal. JACC Clin Electrophysiol. 2021;S2405-500X(21) 00327-3. PubMed

Connolly S.J., Dorian P., Roberts R.S., et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165–171. PubMed

Santangeli P., Muser D., Maeda S., et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016;13:1552–1559. PubMed

Piccini J.P., Berger J.S., O’Connor C.M. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245–1253. PubMed

Sapp J.L., Wells G.A., Parkash R., et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111–121. PubMed

Papageorgiou N., Providência R., Bronis K., et al. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. Europace. 2018;20:682–691. PubMed

Peretto G., Sala S., Rizzo S., et al. Arrhythmias in myocarditis: state of the art. Heart Rhythm. 2019;16:793–801. PubMed

Cronin E.M., Bogun F.M., Maury P., et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: executive summary. Heart Rhythm. 2020;17:e155–e205. PubMed PMC

Peretto G., Sala S., Basso C., Della Bella P. Programmed ventricular stimulation in patients with active vs previous arrhythmic myocarditis. J Cardiovasc Electrophysiol. 2020;31:692–701. PubMed

Al-Khatib S.M., Stevenson W.G., Ackerman M.J., et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary. J Am Coll Cardiol. 2018;72:1677–1749. PubMed

Connolly S.J., Gent M., Roberts R.S., et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–1302. PubMed

Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583. PubMed

Kuck K.H., Cappato R., Siebels J., Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH) Circulation. 2000;102:748–754. PubMed

Wyse D.G., Friedman P.L., Brodsky M.A., et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001;38:1718–1724. PubMed

Ladejobi A., Pasupula D.K., Adhikari S., et al. Implantable defibrillator therapy in cardiac arrest survivors with a reversible cause. Circ Arrhythm Electrophysiol. 2018;11 PubMed

Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883. PubMed

Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–1890. PubMed

Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237. PubMed

Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940. PubMed

Zabel M., Willems R., Lubinski A., et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020;41:3437–3447. PubMed PMC

Schrage B., Uijl A., Benson L., et al. Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish Heart Failure Registry. Circulation. 2019;140:1530–1539. PubMed

Køber L., Thune J.J., Nielsen J.C., et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–1230. PubMed

Beggs S.A.S., Jhund P.S., Jackson C.E., McMurray J.J.V., Gardner R.S. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart. 2018;104:144–150. PubMed

Shen L., Jhund P.S., Petrie M.C., et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41–51. PubMed

Dagres N., Peek N., Leclercq C., Hindricks G. The PROFID project. Eur Heart J. 2020;41:3781–3782. PubMed PMC

Tan V.H., Wilton S.B., Kuriachan V., Sumner G.L., Exner D.V. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:164–170. PubMed

Scott P.A., Silberbauer J., McDonagh T.A., Murgatroyd F.D. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: a meta-analysis. Heart Rhythm. 2014;11:828–835. PubMed

Knops R.E., Olde Nordkamp L.R.A., Delnoy P.-P.H.M., et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383:526–536. PubMed

Masri A., Altibi A.M., Erqou S., et al. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a systematic review and meta-analysis. JACC Clin Electrophysiol. 2019;5:152–161. PubMed PMC

Olgin J.E., Lee B.K., Vittinghoff E., et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and per-protocol analyses. J Cardiovasc Electrophysiol. 2020;31:1009–1018. PubMed PMC

Kirian K.B., Sears S.F., Shea J.B. How to respond to an implantable cardioverter-defibrillator recall. Circulation. 2009;119:e189–e191. PubMed

Caceres J., Jazayeri M., McKinnie J., et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989;79:256–270. PubMed

Stevenson W.G., Khan H., Sager P., et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation. 1993;88:1647–1670. PubMed

de Bakker J.M., van Capelle F.J., Janse M.J., et al. Slow conduction in the infarcted human heart. “Zigzag” course of activation. Circulation. 1993;88:915–926. PubMed

Hsia H.H., Callans D.J., Marchlinski F.E. Characterization of endocardial electrophysiological substrate in patients with nonischemic cardiomyopathy and monomorphic ventricular tachycardia. Circulation. 2003;108:704–710. PubMed

Stevenson W.G., Wilber D.J., Natale A., et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773–2782. PubMed

Jaïs P., Maury P., Khairy P., et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012;125:2184–2196. PubMed

Di Biase L., Burkhardt J.D., Lakkireddy D., et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy. J Am Coll Cardiol. 2015;66:2872–2882. PubMed

Berruezo A., Fernández-Armenta J., Andreu D., et al. Scar dechanneling: new method for scar-related left ventricular tachycardia substrate ablation. Circ Arrhythm Electrophysiol. 2015;8:326–336. PubMed

Tzou W.S., Frankel D.S., Hegeman T., et al. Core isolation of critical arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. Circ Arrhythm Electrophysiol. 2015;8:353–361. PubMed

Vergara P., Trevisi N., Ricco A., et al. Late potentials abolition as an additional technique for reduction of arrhythmia recurrence in scar related ventricular tachycardia ablation. J Cardiovasc Electrophysiol. 2012;23:621–627. PubMed

Andreu D., Penela D., Acosta J., et al. Cardiac magnetic resonance–aided scar dechanneling: Influence on acute and long-term outcomes. Heart Rhythm. 2017;14:1121–1128. PubMed

Yokokawa M., Kim H.M., Baser K., et al. Predictive value of programmed ventricular stimulation after catheter ablation of post-infarction ventricular tachycardia. J Am Coll Cardiol. 2015;65:1954–1959. PubMed

Haïssaguerre M., Shoda M., Jaïs P., et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962–967. PubMed

Knecht S., Sacher F., Wright M., et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol. 2009;54:522–528. PubMed

Dukkipati S.R., Koruth J.S., Choudry S., Miller M.A., Whang W., Reddy V.Y. Catheter ablation of ventricular tachycardia in structural heart disease. J Am Coll Cardiol. 2017;70:2924–2941. PubMed

Zeppenfeld K. Ventricular tachycardia ablation in nonischemic cardiomyopathy. JACC Clin Electrophysiol. 2018;4:1123–1140. PubMed

Guandalini G.S., Liang J.J., Marchlinski F.E. Ventricular tachycardia ablation. JACC Clin Electrophysiol. 2019;5:1363–1383. PubMed

Dinov B., Fiedler L., Schönbauer R., et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129:728–736. PubMed

Proietti R., Essebag V., Beardsall J., et al. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace. 2015;17:461–467. PubMed

Vaseghi M., Hu T.Y., Tung R., et al. Outcomes of catheter ablation of ventricular tachycardia based on etiology in nonischemic heart disease: an International Ventricular Tachycardia Ablation Center collaborative study. JACC Clin Electrophysiol. 2018;4:1141–1150. PubMed PMC

Tung R., Raiman M., Liao H., et al. Simultaneous endocardial and epicardial delineation of 3D reentrant ventricular tachycardia. J Am Coll Cardiol. 2020;75:884–897. PubMed

Shirai Y., Liang J.J., Santangeli P., et al. Comparison of the ventricular tachycardia circuit between patients with ischemic and nonischemic cardiomyopathies: detailed characterization by entrainment. Circ Arrhythm Electrophysiol. 2019;12 PubMed

Sosa E., Scanavacca M., D’Avila A., et al. Endocardial and epicardial ablation guided by nonsurgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol. 1998;9:229–239. PubMed

Santangeli P., Zado E.S., Supple G.E., et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:1413–1421. PubMed

Kumar S., Baldinger S.H., Gandjbakhch E., et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol. 2016;68:2299–2307. PubMed

Tavares L., Lador A., Fuentes S., et al. Intramural venous ethanol infusion for refractory ventricular arrhythmias: outcomes of a multicenter experience. JACC Clin Electrophysiol. 2020;6:1420–1431. PubMed

Tokuda M., Sobieszczyk P., Eisenhauer A.C., et al. Transcoronary ethanol ablation for recurrent ventricular tachycardia after failed catheter ablation: an update. Circ Arrhythm Electrophysiol. 2011;4:889–896. PubMed

Igarashi M., Nogami A., Fukamizu S., et al. Acute and long-term results of bipolar radiofrequency catheter ablation of refractory ventricular arrhythmias of deep intramural origin. Heart Rhythm. 2020;17:1500–1507. PubMed

Nguyen D.T., Tzou W.S., Sandhu A., et al. Prospective multicenter experience with cooled radiofrequency ablation using high impedance irrigant to target deep myocardial substrate refractory to standard ablation. JACC Clin Electrophysiol. 2018;4:1176–1185. PubMed

Stevenson W.G., Tedrow U.B., Reddy V., et al. Infusion needle radiofrequency ablation for treatment of refractory ventricular arrhythmias. J Am Coll Cardiol. 2019;73:1413–1425. PubMed

Anter E., Hutchinson M.D., Deo R., et al. Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4:494–500. PubMed

Cuculich P.S., Schill M.R., Kashani R., et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med. 2017;377:2325–2336. PubMed PMC

Neuwirth R., Cvek J., Knybel L., et al. Stereotactic radiosurgery for ablation of ventricular tachycardia. Europace. 2019;21:1088–1095. PubMed

Reddy V.Y., Reynolds M.R., Neuzil P., et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657–2665. PubMed PMC

Kuck K.-H., Schaumann A., Eckardt L., et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31–40. PubMed

Willems S., Tilz R.R., Steven D., et al. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): a multicenter randomized trial. Circulation. 2020;141:1057–1067. PubMed

Tung R., Vaseghi M., Frankel D.S., et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997–2007. PubMed PMC

Fudim M., Boortz-Marx R., Ganesh A., et al. Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2017;28:1460–1467. PubMed

Do D.H., Bradfield J., Ajijola O.A., et al. Thoracic epidural anesthesia can be effective for the short-term management of ventricular tachycardia storm. J Am Heart Assoc. 2017;6 PubMed PMC

Vaseghi M., Barwad P., Malavassi Corrales F.J., et al. Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol. 2017;69:3070–3080. PubMed PMC

Duffee D.F., Shen W.K., Smith H.C. Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy. Mayo Clin Proc. 1998;73:430–433. PubMed

Walters T.E., Rahmutula D., Szilagyi J., et al. Left ventricular dyssynchrony predicts the cardiomyopathy associated with premature ventricular contractions. J Am Coll Cardiol. 2018;72:2870–2882. PubMed

Baman T.S., Lange D.C., Ilg K.J., et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865–869. PubMed

Mountantonakis S.E., Frankel D.S., Gerstenfeld E.P., et al. Reversal of outflow tract ventricular premature depolarization–induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm. 2011;8:1608–1614. PubMed

Deyell M.W., Park K.-M., Han Y., et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9:1465–1472. PubMed

Penela D., Fernández-Armenta J., Aguinaga L., et al. Clinical recognition of pure premature ventricular complex-induced cardiomyopathy at presentation. Heart Rhythm. 2017;14:1864–1870. PubMed

Yokokawa M., Siontis K.C., Kim H.M., et al. Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation. Heart Rhythm. 2017;14:1695–1701. PubMed

Laurent G., Saal S., Amarouch M.Y., et al. Multifocal ectopic Purkinje-related premature contractions: a new SCN5A-related cardiac channelopathy. J Am Coll Cardiol. 2012;60:144–156. PubMed

Miyamoto K., Aiba T., Kimura H., et al. Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. Heart Rhythm. 2015;12:596–603. PubMed

Kowlgi G.N., Cha Y.-M. Management of ventricular electrical storm: a contemporary appraisal. Europace. 2020;22:1768–1780. PubMed

Guerra F., Shkoza M., Scappini L., Flori M., Capucci A. Role of electrical storm as a mortality and morbidity risk factor and its clinical predictors: a meta-analysis. Europace. 2014;16:347–353. PubMed

Noda T., Kurita T., Nitta T., et al. Significant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac defibrillator. Int J Cardiol. 2018;255:85–91. PubMed

Vergara P., Tung R., Vaseghi M., et al. Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival. Heart Rhythm. 2018;15:48–55. PubMed

Aldhoon B., Wichterle D., Peichl P., Čihák R., Kautzner J. Outcomes of ventricular tachycardia ablation in patients with structural heart disease: the impact of electrical storm. PLoS One. 2017;12 PubMed PMC

Muser D., Liang J.J., Castro S.A., et al. Outcomes with prophylactic use of percutaneous left ventricular assist devices in high-risk patients undergoing catheter ablation of scar-related ventricular tachycardia: a propensity-score matched analysis. Heart Rhythm. 2018;15:1500–1506. PubMed

Mathuria N., Wu G., Rojas-Delgado F., et al. Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol. 2017;48:27–34. PubMed

Mariani S., Napp L.C., Lo Coco V., et al. Mechanical circulatory support for life-threatening arrhythmia: a systematic review. Int J Cardiol. 2020;308:42–49. PubMed

Luni F.K., Zungsontiporn N., Farid T., et al. Percutaneous left ventricular assist device support during ablation of ventricular tachycardia: a meta-analysis of current evidence. J Cardiovasc Electrophysiol. 2019;30:886–895. PubMed

Turagam M.K., Vuddanda V., Koerber S., et al. Percutaneous ventricular assist device in ventricular tachycardia ablation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2019;55:197–205. PubMed

Vergara P., Tzou W.S., Tung R., et al. Predictive score for identifying survival and recurrence risk profiles in patients undergoing ventricular tachycardia ablation: the I-VT score. Circ Arrhythm Electrophysiol. 2018;11 PubMed PMC

Cikes M., Jakus N., Claggett B., et al. Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. Eur J Heart Fail. 2019;21:1129–1141. PubMed

Makki N., Mesubi O., Steyers C., Olshansky B., Abraham W.T. Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. Am J Cardiol. 2015;116:1385–1390. PubMed

Galand V., Flécher E., Auffret V., et al. Predictors and clinical impact of late ventricular arrhythmias in patients with continuous-flow left ventricular assist devices. JACC Clin Electrophysiol. 2018;4:1166–1175. PubMed